Get all premium features to the best stock analysis tool

Perimeter Medical Imaging AI, Inc. (PINK:CA) Q2 2026 Earnings Call Transcript

Results characterized by continued strong commercial momentum and improved operating performance Conference call/webcast today at 5:00 pm ET TORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today reported preliminary financial results for its second quarter ended June 30, 2026, and provided a corporate update. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

TORONTO and DALLAS, Aug. 13, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its second quarter 2026 financial and operating results after market close on Thursday, August 20, 2026. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.

Health system is first to commercially deploy Claire, the only FDA-approved, AI-enabled imaging device for margin assessment during breast-conserving surgery in the U.S. Claire is designed to enhance surgeons' ability to detect difficult-to-see cancer - far beyond what's visible to the naked eye - in real-time in the OR TORONTO and DALLAS, Aug. 13, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") (TSXV: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, today announced that Intermountain Health, the largest nonprofit health system in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter's Claire OCT System™, the only FDA-approved imaging device that uses AI during breast cancer surgery to help surgeons see microscopic tissue structures - where cancer can be difficult to detect - in real-time, for margin assessment. The stakes are significant: about one in five patients needs follow-up breast cancer surgeries because cancer wasn't detected in the operating room the first time.1 "Every breast surgeon wants to give their patient the best possible chance of completing treatment in a single surgery, but microscopic cancer can be difficult to identify in the operating room," said Dr. Teresa Reading, a breast surgeon at Intermountain Health LDS Hospital in Salt Lake City.